Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome
Zealand Pharma · Short Bowel Syndrome (SBS)
Phase 3
Active, not recruiting
28
2026-07
Industry sponsor intelligence
Zealand PharmaClinical Pipeline.
Lead-sponsor view of Zealand Pharma's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 19
- Recruiting
- 2
- Active
- 5
- Completed
- 12
- Results posted
- 2
- Avg enrollment
- 94
Pipeline overview
Programs by phase and activity.
Velocity
Zealand Pharma trials by start year
Study start year · indexed snapshot
Development
Trials by phase
19phase labels
Early Phase 10
Phase 19
Phase 23
Phase 37
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Glepaglutide → | 11 | 4 | 1 | 6 | 0 | 4 |
| Glucagon → | 1 | 0 | 0 | 1 | 0 | 1 |
| Petrelintide → | 7 | 5 | 2 | 0 | 0 | 2 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
Zealand Pharma · Congenital Hyperinsulinism
Phase 3
Active, not recruiting
42
2026-07
Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
Zealand Pharma · Impaired Hepatic Function
Phase 1
Recruiting
36
2026-07
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
Zealand Pharma · Short Bowel Syndrome
Phase 3
Recruiting
90
2026-04
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
Zealand Pharma · Short Bowel Syndrome
Phase 3
Active, not recruiting
129
2026-02
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
Zealand Pharma · Short Bowel Syndrome
Phase 3
Active, not recruiting
145
2026-01
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Zealand Pharma · Overweight · Type 2 Diabetes
Phase 2
Active, not recruiting
221
2026-01
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
Zealand Pharma · Obesity & Overweight
Phase 1
Completed
48
2026-04
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
Zealand Pharma · Obesity
Phase 2
Completed
493
2026-03
Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function
Zealand Pharma · Renal Impairment
Phase 1
Completed
39
2026-01
Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)
Zealand Pharma · Short Bowel Syndrome
Phase 3
Completed
106
2025-07
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Zealand Pharma · Short Bowel Syndrome
Phase 3
Completed
12
2024-11
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants
Zealand Pharma · Overweight · Healthy Volunteers
Phase 1
Completed
68
2024-06
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants
Zealand Pharma · Overweight · Healthy Volunteers
Phase 1
Completed
64
2023-01
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
Zealand Pharma · Healthy
Phase 1
Completed
85
2021-07
Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function
Zealand Pharma · Renal Impairment
Phase 1
Completed
16
2020-11
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
Zealand Pharma · Healthy Subjects
Phase 1
Completed
75
2017-12
Showing 10 of 12 studies
Search sponsor records
All Zealand Pharma studies.
This page groups studies where Zealand Pharma is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
19 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT07228403Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel SyndromeJul 30, 2026NCT03941236Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital HyperinsulinismJul 9, 2026NCT07682818Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic FunctionJul 6, 2026NCT07197944Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBSApr 20, 2026NCT07338214Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product ConcentrationsApr 8, 2026NCT06662539Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesMar 23, 2026NCT04881825Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension TrialFeb 2, 2026NCT03905707Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBSJan 30, 2026NCT07076030Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal FunctionJan 28, 2026NCT06926842Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)Jan 15, 2026